Compugen Ltd. (NASDAQ:CGEN) – Investment analysts at Jefferies Financial Group decreased their Q2 2019 earnings estimates for Compugen in a research note issued to investors on Monday, May 20th. Jefferies Financial Group analyst P. Welford now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, down from their prior estimate of ($0.13). Jefferies Financial Group also issued estimates for Compugen’s Q3 2019 earnings at ($0.14) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at ($0.51) EPS, FY2021 earnings at ($0.61) EPS, FY2022 earnings at ($0.71) EPS and FY2023 earnings at ($0.82) EPS.
A number of other analysts have also recently commented on CGEN. Zacks Investment Research upgraded Compugen from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Thursday. Oppenheimer set a $9.00 target price on Compugen and gave the stock a “buy” rating in a research report on Tuesday, February 26th.
Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 20th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03.
Institutional investors and hedge funds have recently bought and sold shares of the company. RBF Capital LLC acquired a new stake in shares of Compugen during the fourth quarter worth about $30,000. Raymond James Financial Services Advisors Inc. increased its position in shares of Compugen by 72.4% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 26,201 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 11,000 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Compugen during the fourth quarter worth about $60,000. Jane Street Group LLC acquired a new stake in shares of Compugen during the third quarter worth about $128,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Compugen during the first quarter worth about $140,000. Institutional investors and hedge funds own 27.86% of the company’s stock.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Read More: Portfolio Manager
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.